June 29, 2020
This article was originally published by Hostpital and Healthcare. Australians with newly diagnosed multiple myeloma (MM) can now access a treatment regimen combining Revlimid (lenalidomide), Velcade (bortezomib) and dexamethasone on the Pharmaceutical Benefits Scheme (PBS). Known as triplet therapy, each drug in the combination has a different mechanism of action to kill myeloma cells, and all work...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand